Strides Pharma Science Limited (STAR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Strides Pharma Science Limited (STAR) has a cash flow conversion efficiency ratio of 0.060x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs1.20 Billion ≈ $13.00 Million USD) by net assets (Rs19.94 Billion ≈ $215.59 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Strides Pharma Science Limited - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Strides Pharma Science Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Strides Pharma Science Limited balance sheet liabilities for a breakdown of total debt and financial obligations.
Strides Pharma Science Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Strides Pharma Science Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bangkok Chain Hospital Public Company Limited
BK:BCH-R
|
0.032x |
|
Wuxi ETEK Microelectronics Co Ltd
SHG:688601
|
-0.008x |
|
Ina Invest Holding AG
SW:INA
|
0.015x |
|
Gilat Satellite Networks Ltd
TA:GILT
|
-0.013x |
|
Sinoseal Holding Co Ltd
SHE:300470
|
0.038x |
|
NeoGenomics Inc
NASDAQ:NEO
|
0.002x |
|
Quechen Silicon Chemical Co. Ltd.
SHG:605183
|
0.049x |
|
Sinodata Co Ltd
SHE:002657
|
0.002x |
Annual Cash Flow Conversion Efficiency for Strides Pharma Science Limited (2005–2025)
The table below shows the annual cash flow conversion efficiency of Strides Pharma Science Limited from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Strides Pharma Science Limited.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs25.86 Billion ≈ $279.72 Million |
Rs6.84 Billion ≈ $74.01 Million |
0.265x | -21.81% |
| 2024-03-31 | Rs20.72 Billion ≈ $224.05 Million |
Rs7.01 Billion ≈ $75.82 Million |
0.338x | +1555.68% |
| 2023-03-31 | Rs21.73 Billion ≈ $234.99 Million |
Rs444.11 Million ≈ $4.80 Million |
0.020x | +118.89% |
| 2022-03-31 | Rs23.83 Billion ≈ $257.75 Million |
Rs-2.58 Billion ≈ $-27.88 Million |
-0.108x | -163.23% |
| 2021-03-31 | Rs28.14 Billion ≈ $304.32 Million |
Rs4.81 Billion ≈ $52.07 Million |
0.171x | +116.77% |
| 2020-03-31 | Rs25.95 Billion ≈ $280.60 Million |
Rs2.05 Billion ≈ $22.15 Million |
0.079x | +268.20% |
| 2019-03-31 | Rs28.02 Billion ≈ $302.99 Million |
Rs600.55 Million ≈ $6.49 Million |
0.021x | -70.10% |
| 2018-03-31 | Rs26.09 Billion ≈ $282.18 Million |
Rs1.87 Billion ≈ $20.23 Million |
0.072x | -28.48% |
| 2017-03-31 | Rs28.74 Billion ≈ $310.86 Million |
Rs2.88 Billion ≈ $31.16 Million |
0.100x | +306.53% |
| 2016-03-31 | Rs29.06 Billion ≈ $314.27 Million |
Rs716.57 Million ≈ $7.75 Million |
0.025x | -65.60% |
| 2015-03-31 | Rs11.64 Billion ≈ $125.84 Million |
Rs834.00 Million ≈ $9.02 Million |
0.072x | +135.70% |
| 2014-03-31 | Rs10.82 Billion ≈ $117.07 Million |
Rs-2.17 Billion ≈ $-23.51 Million |
-0.201x | -413.53% |
| 2013-03-31 | Rs20.98 Billion ≈ $226.90 Million |
Rs1.34 Billion ≈ $14.53 Million |
0.064x | -80.13% |
| 2012-03-31 | Rs14.18 Billion ≈ $153.34 Million |
Rs4.57 Billion ≈ $49.43 Million |
0.322x | +54.77% |
| 2011-03-31 | Rs15.55 Billion ≈ $168.20 Million |
Rs3.24 Billion ≈ $35.03 Million |
0.208x | +255.34% |
| 2010-03-31 | Rs10.90 Billion ≈ $117.83 Million |
Rs638.65 Million ≈ $6.91 Million |
0.059x | -70.36% |
| 2009-03-31 | Rs5.96 Billion ≈ $64.42 Million |
Rs1.18 Billion ≈ $12.74 Million |
0.198x | -41.18% |
| 2008-03-31 | Rs2.94 Billion ≈ $31.74 Million |
Rs987.01 Million ≈ $10.67 Million |
0.336x | +34.31% |
| 2007-03-31 | Rs4.31 Billion ≈ $46.59 Million |
Rs1.08 Billion ≈ $11.66 Million |
0.250x | +9.80% |
| 2006-03-31 | Rs3.47 Billion ≈ $37.48 Million |
Rs790.26 Million ≈ $8.55 Million |
0.228x | -33.74% |
| 2005-03-31 | Rs2.18 Billion ≈ $23.54 Million |
Rs749.22 Million ≈ $8.10 Million |
0.344x | -- |
About Strides Pharma Science Limited
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products f… Read more